Skip to content
‹ Back to IndustriesHealthcare

Ultrasound Technology to Diagnose and Treat Cardiovascular Disease

Ultrasound analysis leads the charge in advancements in diagnosing and treating cardiovascular disease. Intel’s Yehudit Levi and DiA Imaging Analysis’ Hila Goldman-Aslan joined Michelle Dawn Mooney for insights on the AI and technology advancements in ultrasound that provide better diagnosis and treatment of cardiovascular disease. Hila Goldman-Aslan says that early detection is the go-to strategy…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Ultrasound analysis leads the charge in advancements in diagnosing and treating cardiovascular disease. Intel’s Yehudit Levi and DiA Imaging Analysis’ Hila Goldman-Aslan joined Michelle Dawn Mooney for insights on the AI and technology advancements in ultrasound that provide better diagnosis and treatment of cardiovascular disease.

Hila Goldman-Aslan says that early detection is the go-to strategy to prevent a significant cardiac incident or death. “And ultrasound is the leading modality to identify those abnormalities in the heart, and it’s been increasingly used in all kinds of settings. You can see an ultrasound and cardiac ultrasound being used at the point of care in the emergency rooms and the ICU.”

A 2020 article from the American College of cardiology notes a rise in cardiovascular disease. With one-third of global deaths in 2019 attributed to cardiovascular disease, it is critical to find preventative solutions to reduce these alarming numbers. And this situation is where AI can play an essential role. “Artificial intelligence is all about data,” says Yehudit Levi. “The health segment is unique in the sense that a lot of medical records have been collected through the years. Artificial intelligence software enables processing these masses of data.” The insights gleaned from all this data and knowledge, once made accessible to the medical staff, help highlight abnormalities that might otherwise prove difficult to detect.

DiA Imaging Analysis powered through Intel technology strives to allow for more efficient cardiovascular results and better treatment. “We see physicians looking for more automated procedures and processes to help them make better decisions based on more objective information,” Goldman-Aslan says. Until recently, the review of ultrasound images relied solely on the operator, which creates a layer of subjectivity. With AI analysis, the process becomes more objective and provides better information for the cardiovascular team to make decisions. The increase in cardiac procedures and a shortage of staff analysts available make DiA Imaging ultrasound analysis solutions integral.

“Improving the diagnostic time is super important,” Levi stresses. “It allows more patients to be diagnosed.” Together, DiA and Intel make these ultrasound capabilities scalable for healthcare.

Learn more about Health and Life Sciences by connecting with Yehudit Levi and Hila Goldman-Aslan on LinkedIn or visit: 

 Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Internet of Things Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

  • 01Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.
  • 02Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.
  • 03Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Nov 3, 2026

Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million

Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million

Rockwell Medical agreed to acquire most of Vantive's hemodialysis business for $125 million in base consideration, plus up to $45 million in contingent payments, with closing expected mid-2027. The deal includes hemodialysis concentrates, machines, water treatment systems, and Vantive's Medolla, Italy manufacturing facility; the combined business could generate $400-450 million annually, depending on various factors.

  • 01Rockwell Medical acquires Vantive's hemodialysis concentrates, AK 98 machines, water treatment systems, and one-million-square-foot Medolla, Italy manufacturing campus for $125 million base price plus up to $45 million contingent on revenue and EBITDA milestones.
  • 02Combined business targeted to generate $400-450 million in annual revenue depending on operating performance, exchange rates, market conditions and integration.
  • 03Vantive's dialyzer portfolio, including Theranova dialyzer for expanded hemodialysis, remains with Vantive; the company will focus on home dialysis and critical care after divestiture.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512